<SEC-DOCUMENT>0001178913-20-001627.txt : 20200527
<SEC-HEADER>0001178913-20-001627.hdr.sgml : 20200527
<ACCEPTANCE-DATETIME>20200527070519
ACCESSION NUMBER:		0001178913-20-001627
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200527
FILED AS OF DATE:		20200527
DATE AS OF CHANGE:		20200527

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		20912721

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2024488.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;"><br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Form 6-K</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">For the month of May 2020</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">COMPUGEN LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <table cellspacing="0" cellpadding="0" id="zce94f8fa24ff4bb5adac74b392848253" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">26&#160;Harokmim Street</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;">On May 27, 2020, Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;)
        issued a press release, a copy of which is filed as Exhibit 99.1 to this Report on Form 6-K and is incorporated by reference herein.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">The information contained in the first and fourth paragraphs and the section titled &#8220;Forward-Looking Statements&#8221; in the press release is
        hereby incorporated by reference into the Company&#8217;s Registration Statement on Form F-3, File No.&#160;<font style="background-color: #FFFFFF;">333-233001.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibits</div>
    &#160;<br>
    <div style="line-height: 1.25;">
      <div>
        <table cellspacing="0" cellpadding="0" id="z1872e48871ef4c44ac82583cbc1a5c1c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 72pt; vertical-align: top; align: right;">
                <div>
                  <div style="line-height: 1.25; font-weight: bold;">Exhibit</div>
                  <div style="line-height: 1.25;"><font style="font-weight: bold;"><u>Number</u></font></div>
                </div>
                <div> <br>
                </div>
                <div><a href="exhibit_99-1.htm">99.1</a></div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div> <font style="font-weight: bold;"><u>Description of Exhibit</u></font></div>
                <div> <br>
                </div>
                <div> <br>
                </div>
                <div><a href="exhibit_99-1.htm">Press Release dated May 27, 2020</a>.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z49d7437f42f04bb898e52a5fb0f7f29a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom;" colspan="3">
            <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: middle;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Date: May 27, 2020</div>
          </td>
          <td style="width: 3%; vertical-align: bottom;">
            <div style="line-height: 1.25;">By:&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid black;">
            <div style="line-height: 1.25;">/s/ Eran Ben Dor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 9.59%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Eran Ben Dor</div>
            <div style="line-height: 1.25;">General Counsel</div>
          </td>
          <td style="width: 9.59%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;"> Exhibit 99.1</font></u><br>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">&#160;<img width="128" height="53" src="image0.jpg">
      <div><br>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">Biomarker-informed strategy targets non-small cell lung, ovarian, breast,<br>
      endometrial and colorectal cancers</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">Initial data expected in H1 2021</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">HOLON, ISRAEL, May 27, 2020 &#8211; <u>Compugen Ltd.</u> (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the
      monotherapy expansion cohort of its ongoing Phase 1 clinical trial of COM701, a first-in-class anti-PVRIG antibody. The selected indications for the monotherapy expansion cohort focus on those more likely to respond to treatment with COM701 based on
      biomarker expression studies and clinical data collected to date. As such, the trial will enroll patients with non-small cell lung, ovarian, breast, endometrial and colorectal cancers.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Erika Hamilton, M.D., Director of Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute and principal investigator in the COM701 Phase 1 study, said, &#8220;There is a significant need to
      develop novel treatments for patients with advanced cancer who are unresponsive to or relapse following treatment with the currently available standard of care immune checkpoint inhibitors. The preliminary signs of anti-tumor activity observed in the
      heavily pretreated, all-comer patient population included two confirmed partial responses in patients with microsatellite stable colon and platinum resistant primary peritoneal cancer which are tumor types typically unresponsive to immune checkpoint
      inhibitors. We are excited to advance to the monotherapy expansion stage of the study potentially offering patients a new effective cancer immunotherapy treatment.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Anat Cohen-Dayag, Ph.D., Compugen&#8217;s President and Chief Executive Officer, added, &#8220;While this monotherapy expansion cohort targets tumor types that are typically unresponsive to cancer immunotherapy, we believe that they
      are more likely to respond to treatment with COM701 based on our expression studies and initial clinical results. Furthermore, in this study we will be collecting biopsies before and during COM701 treatment to allow retrospective analyses of our
      biomarker approach and to help inform our future clinical development plan for COM701. We are encouraged by the progress across our clinical programs and the data we have presented on PVRIG and COM701 to date, as well as the possible clinical
      validation of the TIGIT pathway published by others, which we believe supports our long-standing hypothesis concerning the potential role of the DNAM axis as a foundational axis for cancer immunotherapy."</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The monotherapy expansion cohort of the ongoing Phase 1 open-label COM701 clinical trial (<u>NCT03667716</u>) is designed to assess the safety, tolerability and preliminary anti-tumor activity of 20&#160;mg/kg IV Q4 weeks
      COM701 monotherapy in approximately 20 patients with advanced non-small cell lung, ovarian, breast, endometrial and colorectal cancers who have progressed on standard of care treatment. Expansion cohorts were selected based on preclinical biomarker
      expression and clinical data.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About COM701</div>
    <div style="line-height: 1.25;">COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, and blocks the interaction with its ligand, PVRL2. TIGIT, an immune checkpoint
      discovered computationally by Compugen in 2009, and PVRIG constitute parallel immune checkpoint pathways that counteract DNAM, a costimulatory molecule on T cells and NK cells. Preclinical data suggest that the blockade of PVRIG induces a robust
      anti-tumor immune response and demonstrates synergistic activity when used in combination with inhibitors of TIGIT and/or PD-1. Currently, COM701 is being evaluated in a Phase 1 clinical study. Data from the ongoing study have shown that COM701 is
      well-tolerated and demonstrated preliminary signals of anti-tumor activity in a heavily pretreated patient population.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About Compugen</div>
    <div style="line-height: 1.25;">Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the
      field of cancer immunotherapy. The Company&#8217;s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen&#8217;s antibody targeting TIGIT, is
      in a Phase 1 clinical study. The Company&#8217;s therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and
      related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen&#8217;s shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the
      ticker symbol CGEN. For additional information, please visit Compugen&#8217;s corporate website at <u>www.cgen.com</u>.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
    <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933 and the Securities&#160; Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities
      Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Compugen. Forward-looking statements can be identified by the use of terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain
      these identifying words. Forward-looking statements include, but are not limited to, the expectation that initial data will be available in H1 2021, and the likeliness that the monotherapy expansion cohorts will respond to treatment with COM701 and
      the corresponding focus on the selected indications for the monotherapy expansion cohorts. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen
      to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen&#8217;s operations could be affected by the outbreak and spread of COVID-19, clinical
      development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product, or may not be able to conduct or complete its trials
      on the timelines it expects; Compugen relies, and expects to continue to rely, on third parties to conduct its clinical trials and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or
      meet expected deadlines (including as a result of the effect of the COVID-19), Compugen may experience significant delays in the conduct of its clinical trials; Compugen&#8217;s ability to present data derived from collaborations with its partners is
      dependent in some cases on the agreement of its partners to present such data, and in any event is dependent on our acceptance to present data in relevant conferences; Compugen&#8217;s approach to the discovery of therapeutic products is based on its
      proprietary computational target discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; Compugen&#8217;s
      business model is substantially dependent on entering into collaboration agreements with third parties; and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. These risks and other risks
      are more fully described in the &#8220;Risk Factors&#8221; section of Compugen&#8217;s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to
      time with the SEC. In addition, any forwardlooking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to
      update any forward-looking statements unless required by law.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Company contact:</font><br>
      Elana Holzman<br>
      Director, Investor Relations and Corporate Communications<br>
      Compugen Ltd.<br>
      Email: <u>elanah@cgen.com</u><br>
      Tel: +972 (3) 765-8124</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Investor Relations contact:</font><br>
      Bob Yedid<br>
      LifeSci Advisors, LLC<br>
      Email: <u>bob@lifesciadvisors.com</u><br>
      Tel: +1 (646) 597-6989</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Media contact:</font><br>
      Josephine Belluardo, Ph.D.<br>
      LifeSci Communications<br>
      Email: <u>jo@lifescicomms.com</u><br>
      Tel: +1 (646) 751-4361</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ =P!2  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O 1L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8 %/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQEC7MU% 'Q3_ ,*V\:_]"OJG_@.U?8F@:>ND>'=-TY5VBUM8X< =U4 UI44
#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
